FDA Approves Adalimumab Biosimilar, Samsung Bioepis' Hadlima - The Center for Biosimilars

FDA Approves Adalimumab Biosimilar, Samsung Bioepis' Hadlima  The Center for Biosimilars

The FDA on Tuesday approved Samsung Bioepis' Hadlima (adalimumab-bwwd), referencing Humira. Hadlima, a subcutaneous injection, was cleared for ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases